Ono Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Ono Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Ono Pharmaceutical Co Ltd Strategy Report
- Understand Ono Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ono Pharmaceutical Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Ono Pharmaceutical Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 04 Oct 2017 | Lorem |
| BMS’s Opdivo approval in CRC MSI-H supported by efficacy likeness to Keytruda, off-label use may expand market but roadblocks likely – experts | 23 Jun 2017 | Reynald Castaneda |
| BMS Opdivo/Yervoy myocarditis reports should not cause panic given low incidence and efficacy benefits – oncologists | 18 Nov 2016 | Indrani Datta, Hamish McDougall |
| BMS’ Opdivo, Merck’s Keytruda get reimbursed for off-label Hodgkin’s lymphoma use – oncologists | 21 Apr 2016 | Alaric DeArment |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer